lifestyle.pspl.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ALTERITY THERAPEUTICS LIMITED
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
May 2, 2026
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
May 2, 2026
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
April 30, 2026
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
April 28, 2026
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
April 24, 2026
Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
March 2, 2026
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
February 9, 2026
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
January 24, 2026